Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference Transcript

Dec 05, 2019 / 02:00PM GMT
Release Date Price: $124.23 (+1.84%)
Edward Andrew Tenthoff
Piper Jaffray Companies, Research Division - MD & Senior Research Analyst

I'm a senior biotech analyst at Piper Jaffray. And before I begin our discussion with John Maraganore, the CEO of Alnylam, I'm required to point out certain disclosures regarding the relationship between Piper and Alnylam, which are posted both at the back of the room and also at the registration desk.

So Alnylam is the undisputed leader, the undisputed heavyweight of RNAi therapeutics, now with 2 drugs approved and a rich pipeline of future RNAi therapies. Just 2 weeks ago, The Medicines Company was acquired by Novartis for almost $10 billion for Alnylam's discovered cholesterol-lowering drug, inclisiran.

Here today is a very good, very long-time friend, John Maraganore. John, thanks for being with us to discuss these exciting times for Alnylam.

John M. Maraganore;Edward Andrew Tenthoff
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Thanks. Thank you, Ted, and it is exciting times for the company.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot